Top Page
Nuchev Pty Ltd
(Sydney:NUC)
Nuchev Pty Ltd (NUC) vs. iShares MSCI Australia ETF (EWA)
Nuchev Pty Ltd Business Overview & Revenue Model
Nuchev Pty Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.94M | 22.94M | 11.34M | 8.79M | 9.72M | 10.90M |
| Gross Profit | 10.86M | 10.86M | 3.63M | 1.90M | 2.78M | 3.20M |
| EBITDA | -3.73M | -3.73M | -7.18M | -8.57M | -10.88M | -12.40M |
| Net Income | -3.82M | -3.82M | -7.32M | -8.81M | -11.11M | -13.27M |
Balance Sheet | ||||||
| Total Assets | 17.39M | 17.39M | 20.09M | 15.32M | 17.75M | 28.31M |
| Cash, Cash Equivalents and Short-Term Investments | 3.61M | 3.61M | 7.61M | 7.49M | 5.13M | 14.53M |
| Total Debt | 392.63K | 392.63K | 322.85K | 284.14K | 154.12K | 286.33K |
| Total Liabilities | 6.16M | 6.16M | 5.34M | 2.51M | 1.92M | 1.62M |
| Stockholders Equity | 11.23M | 11.23M | 14.75M | 12.82M | 15.83M | 26.69M |
Cash Flow | ||||||
| Free Cash Flow | -3.93M | -3.93M | -3.74M | -3.38M | -11.62M | -9.86M |
| Operating Cash Flow | -3.74M | -3.74M | -3.73M | -3.26M | -11.61M | -9.49M |
| Investing Cash Flow | -138.16K | -138.16K | -2.19M | -126.83K | -914.20K | 411.90K |
| Financing Cash Flow | -115.53K | -115.53K | 6.06M | 5.78M | -118.28K | 14.16M |
Nuchev Pty Ltd Technical Analysis
Nuchev Pty Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
54 Neutral | AU$35.84M | -1.48 | -31.14% | ― | -15.07% | 29.45% | |
42 Neutral | AU$8.39M | -0.24 | -184.71% | ― | 39.53% | 49.99% | |
40 Underperform | AU$21.17M | -5.17 | -29.43% | ― | 102.21% | 69.47% | |
40 Underperform | AU$33.25M | -0.22 | ― | ― | 1.03% | -52.56% | |
40 Underperform | AU$22.55M | -3.66 | -20.54% | ― | 13.92% | 36.28% |
Nuchev Pty Ltd Corporate Events
Nuchev reported second-quarter FY26 group sales revenue of $5.3 million, down 19% quarter-on-quarter and 13% year-on-year, with steady performance in its core Oli6 retail business offset by a sharp 48% quarterly decline in practitioner-channel revenue amid softer trading conditions. Despite weaker international sales due to shipment timing and delayed launches, the company generated a net operating cash inflow of $0.8 million, ended the quarter with $3.1 million in cash and no debt, and highlighted new product development across both consumer and practitioner lines as a key driver for future portfolio expansion and scale in ANZ and overseas markets.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has disclosed a change in director Elizabeth Jean Smith’s interests following the exercise of unquoted share rights under the company’s Equity Incentive Plan, which was approved at the November 2024 AGM. Smith has received 278,750 ordinary shares in lieu of director fees valued at A$35,680, increasing her holding from no ordinary shares to 278,750, while her unquoted share rights decreased from 491,017 to 212,267, reflecting the vesting and conversion of incentives into equity and further aligning her interests with shareholders.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has announced a change in the interests of director Craig Silbery, following the exercise of unquoted share rights under the company’s Equity Incentive Plan. Silbery acquired 474,746 ordinary shares on 22 January 2026 through the conversion of vested share rights issued in lieu of directors’ fees, increasing his direct holding to 5,560,116 ordinary shares while reducing his unquoted share rights to 350,990. The transaction, approved under the company’s previously endorsed incentive framework, further aligns the director’s remuneration with shareholder interests and reflects ongoing use of equity-based compensation at the company.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has reported a change in director Ben Dingle’s interests following the exercise of unquoted share rights granted under the company’s Equity Incentive Plan in lieu of director fees. Dingle converted vested share rights valued at $61,325 into 479,102 ordinary shares, increasing his direct holding to 479,102 shares while maintaining an additional 37,853,680 shares held indirectly via 402339 Pty Ltd as trustee for the Whiti Trust, with the transaction occurring outside a closed period and reflecting ongoing alignment of director compensation with shareholder equity.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has issued 1,232,598 fully paid ordinary shares without a prospectus under the Corporations Act’s disclosure exemptions, confirming that it remains compliant with its continuous and financial reporting obligations and that there is no undisclosed price-sensitive information requiring release. The cleansing notice supports secondary trading of the newly issued shares by assuring investors that the company’s disclosure record is current, thereby facilitating capital management while maintaining transparency for shareholders and the broader market.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has applied to the ASX for quotation of 1,232,598 new ordinary fully paid shares, to be traded under its existing ticker NUC. The new securities, issued on 22 January 2026 following the exercise or conversion of existing options or convertible instruments, will increase the company’s free float and potentially enhance liquidity for shareholders, reflecting ongoing capital structure activity but without disclosing any broader strategic change in this notice.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has appointed Matt Parker as Interim Chief Financial Officer for six months starting 6 January 2026, bringing more than 25 years of financial and commercial leadership across FMCG, healthcare, manufacturing, retail and civil construction, including previous CFO and company secretary roles at several ASX-listed companies. The appointment signals a strengthening of Nuchev’s financial leadership as it continues to grow its nutritional and wellness portfolio across Australia, New Zealand, China and Vietnam, potentially supporting tighter financial governance and execution during a period of ongoing expansion in highly competitive consumer and practitioner-focused markets.
The most recent analyst rating on (AU:NUC) stock is a Sell with a A$0.12 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has announced the cessation of 4,328,723 share rights due to the lapse of conditional rights that failed to meet specified criteria. This move reduces the company’s issued capital, potentially influencing its market operations and stakeholders while reflecting adjustments to its securities governance strategy.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has announced a change in the director’s interest, specifically involving Meng Zhang, known as Leo. The company has issued 385,454 unquoted share rights to Zhang under its Equity Incentive Plan, in lieu of payment of directors’ fees amounting to $67,033.50. This move, approved at the recent AGM, reflects the company’s strategy to align director compensation with its equity performance, potentially impacting stakeholder perceptions and director engagement.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited announced changes in the interests of its directors due to the issuance of unquoted share rights in lieu of director fees, as approved in their annual meeting. This adjustment, initially omitted due to an administrative oversight, has prompted the company to enhance its transparency and compliance procedures. The changes reflect Nuchev’s commitment to maintaining robust governance practices, which is crucial for its stakeholders and market reputation.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited announced the successful results of its Annual General Meeting, where all resolutions were passed by a poll. This outcome reflects strong shareholder support and may positively impact the company’s governance and strategic direction, reinforcing its position in the nutritional and wellness industry.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has announced its strategic priorities to enhance its global presence and accelerate innovation. The company plans to strengthen its brand, drive sales growth through improved marketing, and maintain financial strength, which could positively impact its market positioning and stakeholder confidence.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has restructured its executive team by transitioning the combined COO/CFO role into a standalone CFO position, leading to the departure of Mick Myers. This change is part of Nuchev’s strategy to support its next phase of growth and streamline operations, following significant contributions from Myers in organizational transformation and strategic agreements.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited announced a correction to a previous market announcement regarding a $2 million unsecured facility, initially omitting the parties involved due to administrative oversight. The facility is funded by two major shareholders, 402339 Pty Ltd ATF the Whiti Trust and H&S Global Holdings Pty Ltd ATF the H&S Investment Unit Trust. The company has revised its procedures to enhance transparency and compliance, reflecting its commitment to maintaining stakeholder trust.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited announced the issuance of 917,467 unquoted securities under an employee incentive scheme, which are subject to transfer restrictions and will not be quoted on the ASX until these restrictions are lifted. This move is part of the company’s strategy to incentivize its workforce, potentially impacting its operational dynamics and aligning employee interests with long-term company performance.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited, a company listed on the ASX under the code NUC, has released its 2025 Corporate Governance Statement, emphasizing its commitment to high standards of corporate governance. The company adheres to the ASX Corporate Governance Principles and Recommendations, ensuring transparency, fair dealing, and stakeholder protection. The statement outlines the company’s governance practices and compliance with the ASX guidelines, highlighting areas where recommendations were not followed and the alternative practices adopted. This approach aims to maintain stakeholder trust and ensure legal compliance.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Pty Ltd has released its 2025 Annual Report, emphasizing its vision to become a global leader as a House of Brands focused on transforming wellness, longevity, and quality of life through therapeutic, future-focused solutions. The report outlines the company’s commitment to inspiring healthier and happier futures, with a focus on risk and governance, directors’ and remuneration reports, and financial statements, indicating a strategic approach to enhancing its market position and stakeholder value.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has announced the notice of its 2025 Annual General Meeting, which will be held virtually on November 28, 2025. This meeting is significant for shareholders as it affects their shareholding and voting rights. The company continues to emphasize its commitment to providing high-quality nutritional and wellness products, reflecting its strategic positioning in the industry.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Pty Ltd reported a 30% increase in group revenue to $6.5 million for Q1 FY26, driven by strong sales in the ANZ region and successful market entry into Vietnam. The company’s Oli6® Nutritional sales showed significant growth, particularly in China and Vietnam, underscoring the brand’s market strength and strategic distribution partnerships. Despite cash flow challenges due to production costs and timing, Nuchev remains focused on profitability and market expansion through new product development and strategic agreements.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.
Nuchev Limited has secured a $2 million unsecured Working Capital Facility funded by two substantial shareholders. This facility will enable the company to expedite its growth plans, providing flexibility to explore further expansion opportunities and aim for positive cash flows and profitability in the short to medium term.
The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.